Anja Kathrin Wege Selected Research

Neoplasms (Cancer)

1/2022	mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
5/2021	CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM).
1/2021	Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6.
1/2020	A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
1/2020	Innovations, challenges, and minimal information for standardization of humanized mice.
11/2018	HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
6/2018	Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy.
4/2010	Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry--possibilities and limitations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anja Kathrin Wege Research Topics

Disease

8	Neoplasms (Cancer) 01/2022 - 04/2010
4	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2010
3	Infections 01/2020 - 01/2012
2	Leishmaniasis 01/2018 - 01/2012
1	Neoplasm Metastasis (Metastasis) 05/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019
1	Liver Failure 01/2019
1	Cholestasis 01/2019
1	Triple Negative Breast Neoplasms 01/2018
1	Visceral Leishmaniasis (Kala Azar) 01/2012
1	Cutaneous Leishmaniasis 01/2012
1	Carcinoma (Carcinomatosis) 04/2010

Drug/Important Bio-Agent (IBA)

2	Estrogen ReceptorsIBA 01/2022 - 11/2018
2	Trastuzumab (Herceptin)FDA Link 05/2021 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2019
2	Complement System Proteins (Complement)IBA 01/2020 - 04/2010
2	Pharmaceutical PreparationsIBA 06/2018 - 01/2012
2	VaccinesIBA 01/2018 - 01/2012
1	Phenobarbital (Luminal)FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	apratastatIBA 05/2021
1	3- (formylhydroxyamino)- 2- (3- phenyl- 1- propyl)butanoic acid (2,2- dimethyl- 1- methylcarbamoyl- 1- propyl)amideIBA 05/2021
1	ChemokinesIBA 05/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	pertuzumabIBA 01/2020
1	Glycochenodeoxycholic Acid (Glycochenodeoxycholate)IBA 01/2019
1	Bile Acids and Salts (Bile Acids)IBA 01/2019
1	Tamoxifen FDA LinkGeneric 11/2018
1	Aromatase InhibitorsIBA 11/2018
1	Estrogens (Estrogen)FDA Link 11/2018
1	curdlanIBA 01/2018
1	dectin 1IBA 01/2018
1	AntigensIBA 01/2018
1	CytokinesIBA 01/2012
1	miltefosine (Impavido)IBA 01/2012
1	Keratins (Keratin)IBA 04/2010

Therapy/Procedure

3	Therapeutics 01/2020 - 06/2018
2	Immunotherapy 06/2018 - 01/2018
1	Heterologous Transplantation (Xenotransplantation) 01/2022
1	Drug Therapy (Chemotherapy) 01/2012